An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane (Q34156603)

31 July 2017

1 reference

title

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

3

Wolfgang Eiermann

0 references

Aman U Buzdar

series ordinal

1

object named as

Aman U Buzdar

1 reference

31 July 2017

John F R Robertson

2

1 reference

PubMed ID

12404296

31 July 2017

Jean-Marc Nabholtz

series ordinal

4

1 reference

PubMed ID

12404296

31 July 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

31 July 2017

1 reference

31 July 2017

95

1 reference

31 July 2017

9

1 reference

31 July 2017

2006-2016

1 reference

31 July 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Aromatase inhibitor development for treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Risks and benefits of aromatase inhibitors in postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Aromatase inhibitors in the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Exemestane: a review of its use in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Arimidex: a potent and selective fourth-generation aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Exemestane (FCE 24304), a new steroidal aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

7 January 2021

Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10908

7 January 2021

Identifiers

DOI

10.1002/CNCR.10908

1 reference

31 July 2017

1 reference

PubMed ID

12404296